Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses [4] - The company's lead program, Annamycin, is a next-generation anthracycline aimed at overcoming multidrug resistance and reducing cardiotoxicity associated with traditional anthracyclines [4] Clinical Trial Update - The company is conducting a Phase 3 pivotal trial named "MIRACLE" to evaluate Annamycin in combination with Cytarabine (AnnAraC) for treating relapsed or refractory acute myeloid leukemia (R/R AML) [2][5] - The MIRACLE trial will be a global study with sites in the US, Europe, and the Middle East [2] - Following a successful Phase 1B/2 study, the company believes it has significantly de-risked the development pathway for Annamycin's potential approval [5] Additional Developments - Moleculin is also developing WP1066, an immune/transcription modulator targeting various cancers, and a portfolio of antimetabolites, including WP1122 for treating pathogenic viruses and certain cancer indications [6]
Moleculin Participates in Virtual Investor "What This Means" Segment